MSGene

MSGene - Gene overview of all published MS-association studies for IL2RA

Gene:

IL2RA (RP11-536K7.1; CD25; IDDM10; IL2R; TCGFR)

View on PDGene

Protein:

interleukin 2 receptor, alpha (Interleukin-2 receptor; interleukin 2 receptor, alpha chain)

Chromosome:

10 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 25 November 2011

1. Case-Control Studies (by ethnic group)
				MS Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result
Caucasian
Akkad, 2009	Germany	CL	4 (detail)	1319 (68%)	P	31.4 (-)	-	908 (47%)	46.7 (-)	Positive
Alcina, 2009	Spain	CL	8 (detail)	798 (68%)	P	-	36 (-)	927 (59%)	38 (-)	Positive
ANZgene, 2009	Overlaps with IMSGC, 2008 (GWAS)	CL,PO	1 (detail)	1618 (72%)	O/M	34.1 (7-67)	-	3413 (-)	-	n.a.
ANZgene, 2009	Australia, New Zealand	CL	1 (detail)	2256 (78%)	O/M	34.5 (4-73)	-	2310 (-)	-	Positive
Aulchenko, 2008	Netherlands (GWAS)	CL	1 (detail)	45 (-)	O/M	-	-	195 (-)	-	Negative
Baranzini, 2008	USA, Netherlands, Switzerland (GWAS)	CL	4 (detail)	978 (67%)	MD1&2	34 (11-61)	47 (21-69)	883 (66%)	46 (21-69)	Negative
Cavanillas, 2010	Overlaps with Alcina, 2009	CL	3 (detail)	771 (69%)	P	-	29 (15-71)	759 (68%)	-	Positive
Cavanillas, 2010	Spain (I)	CL	3 (detail)	430 (65%)	P	-	29 (16-79)	550 (-)	-	Positive
D'Netto, 2009	Canada	CL	2 (detail)	43 (-)	U	-	-	182 (-)	-	Negative
Hoppenbrouwers, 2008	Overlaps with Aulchenko, 2008	CL	2 (detail)	46 (72%)	P	33 + 11 (-)	-	194 (-)	-	n.a.
Hoppenbrouwers, 2009	Overlaps with Aulchenko, 2008	CL	1 (detail)	45 (-)	O/M	-	-	195 (-)	-	n.a.
Hoppenbrouwers, 2009	Netherlands (outbred)	CL	2 (detail)	490 (-)	O/M	-	-	426 (-)	-	Trend
IMSGC, 2007	Overlaps with IMSGC, 2008 (UK)	CL	2 (detail)	928 (73%)	MD1&2	32.6 (13-60)	45.1 (17-79)	1475 (-)	-	n.a.
IMSGC, 2007	Overlaps with IMSGC, 2008 (USA)	CL	2 (detail)	1394 (73%)	MD1&2	33.1 (3-69)	45.4 (18-74)	1512 (-)	-	n.a.
IMSGC, 2007	Overlaps with IMSGC, 2008 (USA, UK)	CL,PO	3 (detail)	931 (75%)	MD1&2	27.8 (10-51)	38.6 (17-59)	2431 (-)	-	n.a.
IMSGC, 2008	Overlaps with Sanna, 2010	CL	2 (detail)	909 (-)	U	-	-	576 (-)	-	Positive
IMSGC, 2008	Australia	CL	2 (detail)	472 (-)	U	-	-	424 (-)	-	Positive
IMSGC, 2008	Belgium	CL	2 (detail)	405 (-)	U	-	-	462 (-)	-	Negative
IMSGC, 2008	Denmark	CL	2 (detail)	504 (-)	U	-	-	541 (-)	-	Positive
IMSGC, 2008	Finland	CL	2 (detail)	561 (-)	U	-	-	1017 (-)	-	Positive
IMSGC, 2008	Germany	CL	2 (detail)	206 (-)	U	-	-	605 (-)	-	Positive
IMSGC, 2008	UK (Northern Ireland)	CL	2 (detail)	683 (-)	U	-	-	532 (-)	-	Positive
IMSGC, 2008	Italy	CL	2 (detail)	863 (-)	U	-	-	775 (-)	-	Negative
IMSGC, 2008	Norway	CL	2 (detail)	738 (-)	U	-	-	1027 (-)	-	Positive
IMSGC, 2008	Spain	CL	2 (detail)	815 (-)	U	-	-	786 (-)	-	Positive
IMSGC, 2008	Sweden	CL	2 (detail)	1100 (-)	U	-	-	1251 (-)	-	Negative
IMSGC, 2008	UK	CL	2 (detail)	2323 (-)	U	-	-	2960 (-)	-	Positive
IMSGC, 2008	USA	CL	2 (detail)	1394 (-)	U	-	-	2466 (-)	-	Positive
IMSGC, 2008	Overlaps with Hoppenbrouwers, 2009 (Netherlands)	CL	2 (detail)	46 (-)	U	-	-	194 (-)	-	n.a.
IMSGC, 2011	Europe, USA, Australia, New Zealand (WTCCC2-GWAS)	CL,PO	2 (detail)	9722 (-)	U	32.3 (-)	44.8 (-)	17376 (-)	-	Positive
IMSGC, 2011	Netherlands (GeneMSA-GWAS)	CL	2 (detail)	230 (74%)	U	33 (-)	46 (-)	232 (-)	-	Positive
IMSGC, 2011	USA (GeneMSA-GWAS)	CL	2 (detail)	486 (76%)	U	33 (-)	48 (-)	431 (-)	-	Positive
IMSGC, 2011	Switzerland (GeneMSA-GWAS)	CL	2 (detail)	253 (74%)	U	33 (-)	45 (-)	208 (-)	-	Positive
IMSGC, 2011	Australia, New Zealand (ANZ-GWAS)	CL	2 (detail)	1618 (72%)	U	34 (-)	-	1988 (-)	-	Positive
IMSGC, 2011	USA (BWH-GWAS)	CL	2 (detail)	973 (72%)	U	33 (-)	47 (-)	2952 (-)	-	Positive
IMSGC, 2011	UK, USA (IMSGC2007-GWAS)	CL,PO	2 (detail)	795 (76%)	U	28 (-)	41 (-)	1679 (-)	-	Positive
Maier, 2009	Overlaps with IMSGC, 2008 (USA, UK)	CL	3 (detail)	2420 (-)	MD1	-	-	9407 (-)	-	Positive
Matesanz, 2007	Overlaps with Alcina, 2009	CL	3 (detail)	346 (-)	P	-	-	413 (-)	-	Positive
Mkhikian, 2011	USA (I)	CL	1 (detail)	1201 (-)	MD1	-	-	1493 (-)	-	Positive
Mkhikian, 2011	USA (II)	CL	1 (detail)	2080 (-)	U	-	-	7060 (-)	-	Positive
Perera, 2009	Overlaps with ANZgene, 2009 (GWAS)	CL	4 (detail)	1146 (-)	O/M	-	-	1309 (-)	-	Positive
Rubio, 2008	Overlaps with ANZgene, 2009 (GWAS)	CL	2 (detail)	1146 (75%)	O/M	32 (7-67)	-	1309 (-)	-	Positive
Sanna, 2010	Italy-Sardinia (GWAS)	CL	1 (detail)	882 (-)	MD1	-	-	872 (-)	-	Positive
Weber, 2008	Overlaps with IMSGC, 2008 (Germany)	CL	2 (detail)	206 (63%)	O/M	-	37.8 (19-59)	605 (-)	-	n.a.
African Descent
Johnson, 2009	USA	CL	1 (detail)	918 (79%)	MD1	-	-	656 (71%)	-	Negative
Other/Mixed
Matiello, 2011	USA	PO	2 (detail)	220 (-)	U	-	-	442 (-)	-	Negative
Pandit, 2010	India	CL	1 (detail)	197 (48%)	MD1	30 + 5.6 (-)	35.4 + 3.2 (-)	197 (49%)	31.2 + 4.4 (-)	Negative

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

2. Family-Based Studies (by ethnic group)
				Affecteds				Unaffecteds
Study	Population	# Polys	# Families	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result
Caucasian
D'Netto, 2009	Overlaps with D'Netto, 2009 (CC)	2 (detail)	43	211 (-)	U	-	-	-	-	n.a.
Hoppenbrouwers, 2009	Canada	2 (detail)		1318 (-)	O/M	-	-	1507 (-)	-	Positive
IMSGC, 2007	Overlaps with IMSGC, 2008 (UK)	2 (detail)	380	380 (75%)	MD1&2	27.4 (10-53)	37.4 (17-58)	-	-	n.a.
IMSGC, 2007	Overlaps with IMSGC, 2008 (USA)	2 (detail)	229	229 (79%)	MD1&2	31.1 (9-51)	39.4 (19-58)	-	-	n.a.
IMSGC, 2007	Overlaps with IMSGC, 2007 (UK-GWAS, CC)	2 (detail)	453	453 (75%)	MD1&2	26.5 (10-48)	38.2 (19-59)	-	-	Positive
IMSGC, 2007	Overlaps with IMSGC, 2007 (USA-GWAS, CC)	2 (detail)	478	478 (74%)	MD1&2	29 (11-51)	39 (17-57)	-	-	Positive
IMSGC, 2008	Belgium	2 (detail)	114	-	U	-	-	-	-	Negative
IMSGC, 2008	Finland	2 (detail)	254	-	U	-	-	-	-	Positive
IMSGC, 2008	France	2 (detail)	540	-	U	-	-	-	-	Positive
IMSGC, 2008	UK	2 (detail)	833	-	U	-	-	-	-	Positive
IMSGC, 2008	USA	2 (detail)	707	-	U	-	-	-	-	Positive
IMSGC, 2008	Italy (Sardinia)	2 (detail)	363	-	U	-	-	-	-	Negative
Maier, 2009	Overlaps with IMSGC, 2008 (USA, UK)	3 (detail)	1282	-	MD1	-	-	-	-	Positive
Ramagopalan, 2009	Canada	1 (detail)	600	1193 (-)	U	-	-	1553 (-)	-	Positive
Weber, 2008	Overlaps with IMSGC, 2008 (France)	2 (detail)	540	540 (70%)	O/M	26.5 (9-47)	41.7 (19-67)	1080 (50%)	-	n.a.

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine MS diagnosis -> "P" (Poser criteria, 1983), "MD1" (McDonald criteria, 2001), "MD2" (revised McDonald criteria, 2005), "MD1&2" (McDonald criteria, 2001 and 2005), "O/M" (other/mixed), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.

Print this page

Email this page

MSDF RSS

Text size

Share & Bookmark

MSGene Recent Updates

MSGene Top Results